NewAmsterdam Pharma prices $416.5M upsized public offering; net proceeds ~$452.6M

NewAmsterdam Pharma Co N.V.

Pricing of 12,117,347 ordinary shares at $24.50/share and 4,882,653 pre-funded warrants at $24.4999/warrant.
Offering upsized from initial $300M to $416.5M; underwriters exercised option to buy additional 2,550,000 shares.
Net proceeds to company expected ~$452.6M after underwriting discounts and estimated offering expenses.
Closing expected on or about December 13, 2024, subject to customary conditions.
Joint book-running managers: Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities, William Blair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.